| Expression pattern: |
DN |
| Associated gene: |
LIMCH1, p53, PUMA, Ago2 |
| Associated microRNA: |
miR-346 |
| Biological function: |
Suppresses cell proliferation, migration and invasion; promotes apoptosis; enhances cisplatin sensitivity; promotes the antitumor effect of cisplatin in vivo. |
| Molecular mechanism: |
Acts as a ceRNA to sponge miR-346, thereby inducing LIMCH1 expression and affecting downstream p53/PUMA levels. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); apoptosis (promotes); chemoresistance (inhibits); p53 signaling (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Wound Healing Assay; Transwell Assay; Western Blot; In Vivo Animal Model; Clinical Sample Validation; Microarray |
| Clinical significance: |
circLDB2 expression was associated with tumor, node, and metastasis (TNM) stage and lymph node metastasis. |
| Description: |
circLDB2 is down-regulated in non-squamous NSCLC and functions as a cytoplasmic ceRNA that sponges miR-346 to increase LIMCH1 expression, thereby inhibiting malignant phenotypes and improving cisplatin sensitivity (with increased p53/PUMA). |
| Confidence score: |
0.8546 |